Slide 1: Preliminary Results Year Ended 30 June 2026
Preliminary Results Year Ended 30 June 2026 Significant strategic progress and £60m share buyback announced
Slide 2: Disclaimer
2 Disclaimer This presentation has been prepared by Genus plc (“Genus” or “the Company”) and has not been independently verified. Genus is solely responsible for the contents of this document and has taken all reasonable care to ensure that the facts stated herein are true and accur ate in all mater
Slide 3: Overview & Headlines
Overview & Headlines Jorgen Kokke Chief Executive Officer
Slide 4: What Genus does
4 What Genus does We produce and sell Our animals exhibit This helps our Our products elite animal genetics valuable traits such customers raise therefore improve to farmers. as increased feed healthier animals farmer profitability Our genetics constitute conversion, that produce and reduce the less
Slide 5: FY26: Significant progress & additional shareholder return
5 FY26: Significant progress & additional shareholder return • Excellent financial performance: Strong growth in adj. PBT (+35%) and adj. EPS (+35%) and very strong free cash flow generation (£62m) • Further PRP milestones: Approvals and/or positive determinations secured in Argentina, Canada, Urugu
Slide 6: Financial Results
Financial Results Andy Russell Chief Financial Officer
Slide 7: Strong FY26 financial performance
7 Strong FY26 financial performance Revenue Adj. PBT 1 Adj. EPS 1 £ 658.1m £ 100.2 m 110.3p (- 2%) (+ 35 %) (+ 35 %) Free Cash Flow 1 Adj. Leverage 1 Adj. ROIC 1 £ 62 m 0.4 x 18.4% Conversion 94 % (FY25: 1.5x) (FY25: 15.0 %) 1. Includes £5.6m milestone receipt from BCA
Slide 8: Financial KPIs: Good overall performance; regional/product variation
8 Financial KPIs: Good overall performance; regional/product variation Genus PIC Genus ABS Adj. Royalty Adj. Op. Adj. Op. Sexed Adj. Op. Adj. Op. 1,2 Revenue Growth Profit 3 Profit Margin 3,4 Volume Profit Profit Margin 4 5 + % £ 130.8 m 30.9 % 8.8 m £ 22.9 m 7.5% (+17%) (+330bps) (+2%) (+ 17%) (+ 1
Slide 9: Strong growth in Group adj. operating profit inc. JVs
9 Strong growth in Group adj. operating profit inc. JVs Group adjusted operating profit inc. JVs Adj. operating profit inc. JVs waterfall £m £m 116.0 3.4 0.6 116.0 30% 5.4 7.8 110 12.2 93.1 5.6 25% 3.8 1.9 85.8 93.1 90 8.4 77.7 78.1 3.7 20% 9.4 In constant currency 2 5.6 3.8 17.7% 70 15% 13.1% 13.8%
Slide 10: Genus PIC: Strong adj. operating profit growth
10 Genus PIC: Strong adj. operating profit growth PIC adjusted operating profit inc. JVs bridge £m • Adj. operating profit inc. JVs increased 17% to £130.8m at a 30.9% margin (16% growth & 29.3% margin exc. Adj. Op. Profit Margin 1 BCA milestones) 30.9% • Strong performance in Latin America driven b
Slide 11: Genus PIC: Strong joint venture performance
11 Genus PIC: Strong joint venture performance Agroceres PIC PIC China 1 Royalty Revenue Adj. Op. Royalty Revenue Adj. Op. Growth Profit Growth Profit Entire Entity +7% £ 38.9 m £ 15.2m +52% (+ 56 %) (+ 81%) Genus Share of Adj. Op. Profit Genus Share Genus Share of Adj. Op. £ 19.1m £ 12.2m of Adj. O
Slide 12: Genus ABS: Continued profit improvement
12 Genus ABS: Continued profit improvement ABS adjusted operating profit bridge £m Adj. Op. • Adjusted operating profit increased 17% to £22.9m at Profit Margin 1 a 7.5% margin 7.5% • VAP continued to be the major driver of ABS profit (FY25: 6.3 %) growth; £9.0m of benefit realised in FY26 comprisin
Slide 13: Significant continuing investment in R&D
13 Significant continuing investment in R&D Genus research and product development 1 Porcine product development % of Genus revenue Genus continues to % of Porcine revenue Lower product invest substantially 11% 11% development spend 13% 50 10% 12% 100 12% 12% 15%in research and 9% primarily due to 1
Slide 14: Statutory Income
14 Statutory Income FY26 FY25 Change Non - cash impacts £m £m £m • £12.8m increase in net IAS 41 biological assets primarily driven by porcine (FY25: £13.3m decrease primarily due to Adjusted operating profit 94.8 81.1 13.7 bovine) Net IAS 41 valuation mvmt on biological 12.8 (13.3) 26.1 Exceptional
Slide 15: Continued strong Free Cash Flow generation
15 Continued strong Free Cash Flow generation Free cash flow 1 bridge Actual currency (£m) (6.8) • Very strong Free Cash Flow generation of 10.0 10.4 £62.0m 11.1 (15.3) • Significant adj. EBITDA increase of £11.1m and 11.7 £10.0m higher JV dividends from Agroceres • Underlying negative working capit
Slide 16: Strong financial position – leverage reduced to 0.4x
16 Strong financial position – leverage reduced to 0.4x Net debt bridge Actual currency (£m ) Significant Net Debt reduction Net Net Debt: Debt: • Net debt decreased to £71.8m at 30 EBITDA 1,2 Free cash flow inc. EBITDA 1,2 June 2026 1.5x lease repayments: 0.4x 6.0 16.4 • Leverage 1,2 reduced to 0.4
Slide 17: FY26 Normalisation
17 FY26 Normalisation Actual currency (£m) FY26 FY26 Normalisation £m Reported Less: 49% of Less: Interest Genus Less: PIC Normalised PIC China impacts PIC China China BCA & pro - One - Off Reported Milestone Hedging forma Production • Milestone receipt of £5.6m in FY26 (£3.7m in FY25) Benefit • PIC
Slide 18: Capital Allocation Performance
18 Capital Allocation Performance Capital Allocation Framework FY26 Performance Maintain a strong balance sheet → target leverage range of 1.0x to 2.0x 0.4 x Leverage at June 2026 Organic Growth Invest in compelling organic £ 73m R&D spend 1 Opportunities profit growth opportunities that can deliver
Slide 19: Strategic Progress
Strategic Progress Jorgen Kokke Chief Executive Officer
Slide 20: Strategic Priorities: Continued focus and momentum
20 Strategic Priorities: Continued focus and momentum 1. 2. 3. Continued growth in Successfully Drive greater porcine, accelerated commercialise PRP and deliver attractive value from bovine growth in China returns from R&D • PIC Global: good royalty revenue • PRP approvals and/or positive • VAP Phas
Slide 21: Compounding PIC royalty revenue
21 1: Compounding PIC royalty revenue Compounding royalty revenue growth… …with a proven revenue model that stabilises earnings and Constant currency £m drives customer loyalty 4 year CAGR 100 NAM 90 +4 % Royalty Model Adjusted 80 LATAM Aligns PIC and Customer Royalty 70 +8 % Benefits/Value Revenue
Slide 22: Strong PIC China, Joint Venture formed
22 1: Strong PIC China, Joint Venture formed Strong FY26 (despite declining pork prices) Positive start to joint venture 100% entity; Constant Currency £m 60 50 Positive, collaborative start to the JV relationship with BCA 40 36 30 Continuing to win new royalty customers despite 28 22 the continuing
Slide 23: Approvals / Favourable Determinations in Argentina, Canada, Uruguay and Peru
23 2: Approvals / Favourable Determinations in Argentina, Canada, Uruguay and Peru Commercialisation process beginning in selected Latin American countries Approved/ favourable determination Peru June 2026 Uruguay March 2026 Canada January 2026 Argentina July 2025 U.S.A. April 2025 Dominican Republi
Slide 24: VAP completing; focus moving to commercial and operational excellence
24 3: VAP completing; focus moving to commercial and operational excellence VAP Phase 1 & 2: Focus Areas VAP Phase 3: Focus Areas Adj. Op. Profit Unified global FY26 Adj. Op. Annualised Adj. Reshaping Benefit leadership Profit Benefit Op. Profit Benefit ABS go - to - Pricing market £21m governance &
Slide 25: ABS journey to medium term double digit operating margins
25 3: ABS journey to medium term double digit operating margins Foundation set by VAP; Clear strategy for growth beyond FY27 Drive top - line via Commercial Excellence ABS Global ➢ Build a higher performing commercial organization Revenue Adj. Op. Profit 1 Adj. Op. Margin 1 ➢ Leverage through repeat
Slide 26: Summary & Outlook
Summary & Outlook Jorgen Kokke Chief Executive Officer
Slide 27: Summary & Outlook
27 Summary & Outlook FY27 Outlook Strong profit and cash generation Resilient underlying profit growth despite cyclical weakness in key agricultural markets Group adj. PBT in constant currency to be in Strategic porcine joint venture line with consensus expectations and formed in China moderately hi
Slide 28: Why Invest In Genus
28 Why Invest In Genus 01 02 03 Growing and resilient Strong positions, leading Significant end - markets products white space Increasing global demand World - class genetics, a well - Significant addressable market for animal protein invested, global supply chain growth through customers gaining an
Slide 29: Q&A
29 Q&A
Slide 30: Appendices
30 Appendices
Slide 31: Technical Guidance
31 Technical Guidance Area FY26 FY27 Expected Impacts Adjusted Income Statement Items Net Interest £15.8m £9m - £11m Effective Tax Rate 27.2% 26% - 28% Foreign Exchange £3.5m tailwind £0m - £2m headwind based on current rates; see Appendix ABS VAP Phase 3 benefit to adjusted operating profit £7.0m £
Slide 32: Pro Forma: Milestones & PIC China Deconsolidation
32 Pro Forma: Milestones & PIC China Deconsolidation Actual currency (£m) FY26 H1 £m Reported Less: 49% of China Less: Genus pro - Less: PIC Normalised PIC China JV & interest Milestone forma One - Off savings (SASAC 1) Production Benefit Revenue 335.6 (25.3) - - 310.3 310.3 Adj. OP ex - JVs 55.7 (8
Slide 33: Pro Forma: Milestones & PIC China Deconsolidation
33 Pro Forma: Milestones & PIC China Deconsolidation Actual currency (£m) FY25 Full Year £m Reported Less: PIC 49% of Less: Genus pro - China China JV & Milestone forma interest (FDA 1) savings Revenue 672.8 (41.3) - - 631.5 Adj. OP ex - JVs 81.1 (9.0 ) - (3.7) 68.4 Share of JVs Profit Before Tax 12
Slide 34: Free Cash Flow
34 Free Cash Flow FY26 FY25 actual actual Cash flow history £m £m (£m) Adjusted operating profit inc. JV 116.0 93.1 114% 115 115% Less: JV profit and non - controlling interests (21.2) (12.0) Depreciation and amortisation 36.1 38.7 95 94% 95% Adjusted EBITDA 130.9 119.8 Cash received from joint vent
Slide 35: Exchange Rate Sensitivity
35 Exchange Rate Sensitivity FY26 FY26 Spot at Profit Genus’s geographic profile Average 1 Closing 07 Sept 2026 Sensitivity £m 2 can lead to translational currency impacts Euro 1.15 1.16 1.17 2.6 Brazilian Real 7.05 6.85 6.95 2.4 We monitor key rates against GBP Mexican Peso 24.0 23.2 23.0 2.2 Lates
Slide 36: Return on Invested Capital
36 Return on Invested Capital FY26 FY25 restated 1 £m £m Adjusted operating profit inc JV 116.0 93.1 Tax rate 27.2% 27.5% Adjusted operating profit after tax 84.4 67.5 Equity attributable to owners of the company 766.7 476.1 Add back: Net debt 71.8 228.2 Pension liability (net of asset) 4.4 6.9 Rela
Slide 37: Sustainability
37 Sustainability FY26 Milestones Porcine Genetic Improvement Index (US$) • Beef on Dairy Life Cycle Assessment: ABS NuEra Genetics reduce the overall environmental footprint of commercial beef on dairy programmes in the U.S. and U.K. by 4.5% to 8.8% FY26 4.08 FY25 4.15 • PRP Life Cycle Assessment:
Slide 38: Proportion of Total Porcine Volumes Under Royalty
38 Proportion of Total Porcine Volumes Under Royalty North America EMEA 97% 97% 97% 97% 97% 79% 80% 80% 79% 78% FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Latin America Asia 67% 71% 67% 84% 83% 57% 60% 77% 70% 66% FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26
Slide 39: Glossary
39 Glossary Artificial insemination (‘AI’) Using semen collected from a bull or boar to Genomic bull A bull which has been assessed through genomic testing. PRP PRRS Resistant Pig. impregnate a cow or sow when in oestrus. Artificial insemination allows a This typically refers to bulls which have not